Literature DB >> 11704886

Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels.

L M Andersson1, L Hagberg, D Fuchs, B Svennerholm, M Gisslén.   

Abstract

The objective of this study was to assess the frequency of blood-brain barrier (BBB) impairment, as measured by the albumin ratio, in neuro-asymptomatic HIV-1-infected individuals without antiretroviral treatment and the correlation between BBB disruption and intrathecal immune activation and HIV-1 RNA levels. Serum and cerebrospinal fluid (CSF) albumin, neopterin, and HIV-1 RNA levels were analysed in 110 neuro-asymptomatic HIV-1-infected individuals at different stages of disease; 63 classified as CDC A, 25 as CDC B, and 22 as CDC C. Increased BBB permeability was found in 17 of 110 (15%) of HIV-1-infected individuals. This proportion was sustained throughout the CDC stages. The albumin ratio was correlated with the CSF neopterin levels (r(s) = 0.36, P < 0.001), the serum neopterin levels (r(s) = 0.37, P < 0.001), and the CSF HIV-1 RNA levels (r(s) = 0.26, P < 0.01), but not with the plasma HIV-1 RNA levels. The correlations between the albumin ratio and the CSF and serum neopterin concentrations and the CSF HIV-1 RNA levels indicate that immune activation and, possibly, intrathecal HIV-1 virus replication are important factors associated with increased BBB permeability in HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704886     DOI: 10.1080/135502801753248123

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  38 in total

1.  Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry.

Authors:  K Takahashi; S L Wesselingh; D E Griffin; J C McArthur; R T Johnson; J D Glass
Journal:  Ann Neurol       Date:  1996-06       Impact factor: 10.422

2.  Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome.

Authors:  T L Katzenstein; C Pedersen; C Nielsen; J D Lundgren; P H Jakobsen; J Gerstoft
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

3.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.

Authors:  G Tibbling; H Link; S Ohman
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

4.  CSF changes in a longitudinal study of 124 neurologically normal HIV-1-infected U.S. Air Force personnel.

Authors:  D W Marshall; R L Brey; C A Butzin; D R Lucey; S M Abbadessa; R N Boswell
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

Review 5.  Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia.

Authors:  Y Persidsky; J Zheng; D Miller; H E Gendelman
Journal:  J Leukoc Biol       Date:  2000-09       Impact factor: 4.962

6.  Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1.

Authors:  D Fuchs; F Chiodi; J Albert; B Asjö; L Hagberg; A Hausen; G Norkrans; G Reibnegger; E R Werner; H Wachter
Journal:  AIDS       Date:  1989-05       Impact factor: 4.177

7.  The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study.

Authors:  J C McArthur; T E Nance-Sproson; D E Griffin; D Hoover; O A Selnes; E N Miller; J B Margolick; B A Cohen; H Farzadegan; A Saah
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

8.  Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome.

Authors:  C A Wiley; C Achim
Journal:  Ann Neurol       Date:  1994-10       Impact factor: 10.422

9.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection.

Authors:  L E Davis; B L Hjelle; V E Miller; D L Palmer; A L Llewellyn; T L Merlin; S A Young; R G Mills; W Wachsman; C A Wiley
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

10.  Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain.

Authors:  C K Petito; K S Cash
Journal:  Ann Neurol       Date:  1992-11       Impact factor: 10.422

View more
  26 in total

1.  Culture of murine brain microvascular endothelial cells that maintain expression and cytoskeletal association of tight junction-associated proteins.

Authors:  Li Song; Joel S Pachter
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

2.  Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis.

Authors:  Raghava Potula; Larisa Poluektova; Bryan Knipe; Jesse Chrastil; David Heilman; Huanyu Dou; Osamu Takikawa; David H Munn; Howard E Gendelman; Yuri Persidsky
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

3.  PPARα and PPARγ protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling.

Authors:  Wen Huang; Ibolya E András; Geun Bae Rha; Bernhard Hennig; Michal Toborek
Journal:  FASEB J       Date:  2011-08-12       Impact factor: 5.191

4.  High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Children.

Authors:  Sarah F Benki-Nugent; Ira Martopullo; Tony Laboso; Nancy Tamasha; Dalton C Wamalwa; Kenneth Tapia; Agnes Langat; Elizabeth Maleche-Obimbo; Christina M Marra; Paul Bangirana; Michael J Boivin; Grace C John-Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

5.  Prevalence and predictors of blood-brain barrier damage in the HAART era.

Authors:  A Calcagno; M C Alberione; A Romito; D Imperiale; V Ghisetti; S Audagnotto; F Lipani; S Raviolo; G Di Perri; S Bonora
Journal:  J Neurovirol       Date:  2014-06-28       Impact factor: 2.643

6.  Central nervous system complications of HIV infection.

Authors:  Serena S Spudich; Beau M Ances
Journal:  Top Antivir Med       Date:  2011 May-Jun

7.  Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy.

Authors:  Elham Rahimy; Fang-Yong Li; Lars Hagberg; Dietmar Fuchs; Kevin Robertson; Dieter J Meyerhoff; Henrik Zetterberg; Richard W Price; Magnus Gisslén; Serena Spudich
Journal:  J Infect Dis       Date:  2017-04-01       Impact factor: 5.226

Review 8.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

9.  Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis.

Authors:  A Calcagno; A Romito; C Atzori; V Ghisetti; C Cardellino; S Audagnotto; E Scarvaglieri; F Lipani; D Imperiale; G Di Perri; S Bonora
Journal:  J Neuroimmune Pharmacol       Date:  2016-11-08       Impact factor: 4.147

10.  Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia.

Authors:  Malcolm J Avison; Avindra Nath; Robin Greene-Avison; Frederick A Schmitt; Rodney A Bales; As'ad Ethisham; Richard N Greenberg; Joseph R Berger
Journal:  J Neurovirol       Date:  2004-08       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.